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  Fucoidan is a sulfated polysaccharide purified from brown 
algae  including  Fucus  vesiculosus  and  has  a  variety  of 
biological  effects  including  mobilization  of  hematopoietic 
progenitor cells. Recently, we demonstrated that fucoidan 
stimulates  the  antigen-presenting  functions  of  dendritic 
c e l l s .  I n  t h i s  s t u d y ,  w e  i n v e s t i g a t e d  t h e  r a d i o p r o t e c t i v e  
effects of fucoidan on bone marrow cells (BMCs), which are 
the  main  cellular  reservoir  for  the  hematopoietic  and 
i m m u n e s y s t em .  T o  e v a l u a t e t h e e ff e ct s  o f  f u co i da n ,  w e 
assayed cell viability and immune responses. In a viability 
assay,  fucoidan  significantly  increased  the  viability  of 
BMCs. Based on the results of flow cytometric analysis, the 
increased viability of fucoidan-treated BMCs was attributed 
to the inhibition of radiation-induced apoptosis. Furthermore, 
fucoidan altered the production of immune-related cytokines 
from BMCs and increased the capability of BMCs to induce 
proliferation of allogeneic splenocytes. Taken together, our 
study demonstrated that fucoidan has radioprotective effects 
on BMCs with respect to cell viability and immunoreactivity. 
These results may provide valuable information, useful in 
the field of radiotherapy.
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Introduction
  Bone marrow contains a variety of cells that are required 
to maintain the hematopoietic and immune systems. On 
exposure to ionizing radiation, bone marrow is profoundly 
damaged and severe immunosuppression occurs. Therefore, 
protection of bone marrow against gamma radiation is 
extremely important in individuals in danger of radiation 
exposure.
  To protect the host against the harmful effects of radiation 
exposure, radioprotective agents have been developed over 
several decades [5]. Although the radioprotective agent 
amifostine has been used in clinical settings [17,22], it 
generates serious side effects, including nausea, probably 
due to its synthetic nature [15]. Recent studies have focused 
on the development of radioprotective agents derived from 
natural sources and that display minimal side effects on 
normal cells [1]. For example, some polysaccharides purified 
from herbs have been shown to have radioprotective and 
immunostimulating effects on host immune cells [9,21].
  Fucoidan is a sulfated polysaccharide purified from brown 
algae, such as Fucus vesiculosus, and has been shown to have 
a variety of biological effects [2,3]. Previous studies have 
indicated that fucoidan stimulates the mobilization of 
hematopoietic progenitor cells (HPCs) from their niche 
within bone marrow to peripheral blood via inhibition of the 
selectin-mediated adhesion of HPCs [3]. In addition, 
fucoidan-induced mobilization of HPCs is associated with 
increased plasma levels of stromal-derived factor-1 in vivo 
[19]. Recently, we demonstrated that fucoidan stimulates 
multiple functions of dendritic cells (DCs), which are potent 
antigen-presenting cells (APCs) in the immune system [10].
  Although the biological functions of fucoidan in hemato-
poietic and immune systems have been studied for many 
years, its radioprotective effects on bone marrow cells 
(BMCs) have not been elucidated. In this study, we 
investigated the protective effects of fucoidan on irradiated 
BMCs. Specifically, we quantified the viability of cells, 
cytokine production, and allostimulatory capability of this 
agent.
Materials and Methods
Animal and reagents
  C57BL/6 and Balb/c mice were purchased from Orient Bio 360    Yun-Young Byon et al.
(Korea) and maintained at our animal facility. Seven to 12 
week-old female mice were used in this study. All 
experiments using animal were performed based on the 
institutional guideline of Cheju National University for 
laboratory animal use and care (Approval No: 20070005). 
Fucoidan, originated from Fucus vesiculosus, was obtained 
from Sigma (USA) and dissolved in phosphate-buffered 
saline (Invitrogen, USA). The endotoxin level of the fucoidan 
preparation was less than 0.1 EU/ml from QCL-1000 
Chromogenic LAL endpoint assay (Lonza Walkersville, USA) 
according to the manufacturer’s protocol.
Preparation of cells and measurement of cell viability
  BMCs were harvested from the femurs and tibias of mice 
of C57BL/6 mice as described in previous report [9]. Any 
contaminated red blood cells were eliminated by ammonium 
chloride-potassium carbonate lysis buffer. To culture BMCs, 
RPMI 1640 media containing 5% fetal bovine serum (FBS), 
2 mM L-glutamine, and 100 U/ml penicillin/ streptomycin 
(Invitrogen, USA) was used. For the cell viability assay, 
BMCs were cultured at a concentration of  2 × 10
5 cells/well 
in 96-well plates and treated with fucoidan before 
irradiation. The cultured wells were incubated with 10 μl/ 
well of Cell Counting Kit-8 solution (CCK-8 solution; 
Dojindo, USA) for 4 h and the optical density (O.D.) of wells 
was measured at 450 nm by using a microplate reader 
(Molecular Devices, USA).
Gamma irradiation
  The BMCs were irradiated using a 
60Co γ-ray source (MDS 
Nordion C-188 standard source) established in the Applied 
Radiological Science Research Institute, Cheju National 
University (Korea). Irradiation on cells was performed 
once at 1 Gy for this study.
Determination of interleukin-12 (IL-12) and tumor 
necrosis factor-alpha (TNF-alpha) production
  Fucoidan (50 μg/ml) was administrated in 1 × 10
6 cells/ml 
of BMCs for 24 h and then single-exposed to gamma 
irradiation. After 24 h, the supernatants were harvested and 
used for the determination of IL-12 and TNF-alpha, the 
representative cytokines of cell-mediated and innate immunity. 
The cytokine concentration of supernatant were measured 
by enzyme-linked immunosorbent assay (ELISA) using 
CytoSet antibody pairs (Biosource International, USA) 
based on the manufacturer’s manual.
Flow cytometric analysis
  BMCs were cultured at a concentration of 1 × 10
6 cells/ml 
in 6-well plates and treated with fucoidan (50 μg/ml) for 24 
h and then irradiated once (1 Gy). After 24 h, the cells were 
harvested and stained for flow cytometric analysis as 
described in our previous report [9]. Briefly, we used 
biotin-labeled anti-Gr-1, anti-I-A
b (MHC II), anti-CD86 
(B7.2) monoclonal antibody as the primary antibody and 
streptavidin-fluorescein isothiocyanate (FITC) as the 
secondary antibody (BD Biosciences, USA). For the 
measurement the percentage of apoptotic cells, cells were 
stained by using annexin V-FITC/propidium iodide (PI) kit 
(Biosource International, USA) as described in the 
manufacturer’s instructions. For the measurement of 
mitochondrial membrane potential, cells were incubated 
with 10 μg/ml rhodamine 123 (Sigma, USA) for 30 min. 
All stained cells were analyzed by using FACSCalibur and 
CellQuest (Beckton Dickinson, USA).
Mixed lymphocyte reaction (MLR)
  BMCs were cultured and treated as we described in flow 
cytometric analysis. Splenocytes obtained from Balb/c mice 
were used as allogeneic responder cells for the co-culture 
with BMCs of C57BL/6 mice as described in previous report 
[9]. 2 × 10
5 cells/well allogeneic splenocytes were co-cultured 
with 1,852∼5 × 10
4 cells/well BMCs in 96-well culture 
plates for 5 days. To minimize the proliferation of BMCs 
themselves in total value, all BMCs were irradiated 
immediately prior to co-culture. The culture medium was 
RPMI 1640 medium containing 10% FBS, 0.1 mM 
non-essential amino acid, 1 mM sodium pyruvate, 2 mM 
L-glutamine, 100 IU/ml penicillin/ streptomycin, and 50 
μM 2-mercaptoethanol (Invitrogen, USA). The co-cultures 
were pulsed with 1 μCi/well 
3H-thymidine (PerkinElmer, 
USA) for last 18 hrs and the incorporated radioactivity in 
cells was measured by a liquid scintillation counter (Wallac 
Microbeta TriLux; PerkinElmer, USA).
Western blot analysis
  BMCs were cultured and treated as previously described 
in flow cytometric analysis section. The cells were 
harvested and then used for Western blot analysis. The 
lysates of treated BMCs were obtained and the Western 
blot analysis was performed as described in a previous 
report [8]. Briefly, proteins blotted on nitrocellulose 
membrane were probed with anti-Bcl-2, Bcl-xL, Bax 
antibody (Santa Cruz Biotechnology, USA), anti-cIAP-1, 
cIAP-2 antibody (Millipore, USA), and anti-β-actin antibody 
(Sigma, USA) and sequentially appropriate horseradish 
peroxidase-labeled secondary antibodies. The blot was 
developed by SuperSignal West Pico Cheminluminescent 
Substrate (Pierce Biotechnology, USA).
Statistical analysis
  Most of data were obtained from three experiments and 
analyzed with Turkey-Kramer multiple comparison tests. 
A p value ＜0.05 was recognized as statistically significant.Radioprotective effects of fucoidan    361
Fig. 1. Fucoidan increases bone marrow cell (BMC) viability. 
Asterisks (*, **, ***) indicate p ＜ 0.05, 0.01, 0.001 vs Non- 
irradiation (NO-IR) control (fucoidan 0 μg/ml) and ##, ### 
indicate p ＜ 0.01, 0.001 vs irradiation (IR) control (fucoidan 0 
μg/ml), respectively.
Fig. 2. Inhibition of bone marrow cell (BMC) apoptosis by fucoidan treatment. (A) Numbers indicate the cell percentage of quadrant. (B)
Numbers indicate the mean fluorescence intensity of all cells and brackets include the percentage of high expressed cells (M1). 
Results
Fucoidan significantly increases BMC viability 
  To examine the effects of fucoidan on BMC viability, we 
cultured BMCs at a concentration of 2 × 10
5 cells/well in 
96-well plates and treated them with fucoidan before 
irradiation (Fig. 1). After culturing the cells, CCK-8 solution 
was added and the O.D. of wells was measured. In the absence 
of fucoidan, control BMCs showed significantly higher 
viability than irradiated BMCs (p＜0.05). Fucoidan 
significantly increased the viability of control BMCs within 
the range of concentration (2∼50 μg/ml) and in irradiated 
BMCs (10∼50  μg/ml). BMCs were cultured without 
cytokines, which may maintain their survival in vivo. Thus, 
it was likely that this manipulation would lead to cytokine 
withdrawal-induced cell death. Irradiation significantly 
decreased the BMC viability. Together, these results suggest 
that fucoidan may protect BMCs from cytokine withdrawal- 
induced cell death and irradiation.
Fucoidan treatment decreases cell death in irradiated 
BMCs 
  For this test, BMCs were cultured at a concentration of 1 × 
10
6 cells/ml in 6-well plates and treated with fucoidan (50 
μg/ml) for 24 h and then irradiated once (1 Gy). After 24 h, 
cells were harvested and used for the cell death measurements. 
Annexin V-FITC/PI staining and rhodamine 123 staining 
were used to confirm the protective effects of fucoidan on 
the viability of irradiated BMCs (Fig. 2). With the annexin 
V-FITC/PI staining (Fig. 2A), we found that fucoidan 
consistently increased the number of viable cells, the 
double-negative cells (annexin V−/PI−). Specifically, 
cell viability was only 15% with irradiation, which increased 
to 62% with fucoidan treatment. In addition, fucoidan 
decreased the ratio of late apoptotic cells (annexin V+/PI+). 
  Mitochondria are known to play a critical role in the 
apoptotic process of cells. Thus, we performed rhodamine 362    Yun-Young Byon et al.
Fig. 3. The altered expression of apoptosis-related molecules in 
fucoidan-treated bone marrow cells. (A) Western blot. (B) Densitometry
of western blot. 
123 staining to determine mitochondrial potential as 
cellular apoptosis decreases the stability of mitochondrial 
potential (Fig. 2B). Our results indicated that irradiation 
decreased mitochondrial potential; however, this was 
recovered by fucoidan treatment. Taken together, our 
results demonstrate that fucoidan increases BMC viability 
following irradiation. These effects may be the result of 
apoptotic inhibition in irradiated BMCs.
Fucoidan treatment alters the expression of apoptosis- 
related molecules in BMCs
  To further investigate the functional role of fucoidan, we 
examined the expression levels of apoptosis-related 
molecules in BMCs. Western blot analysis (Fig. 3) indicated 
that the expression levels of Bcl-2, Bax, and cIAP-1 were 
increased in fucoidan-treated BMCs. In densitometry 
results (B), Bcl-2 and Bax expression was increased in all 
fucoidan-treated BMCs whereas cIAP-1 expression was 
increased only in fucoidan-treated BMCs. However Bcl-xL 
was not detected in these experiments.
Fucoidan  treatment  increases  the  expression  of 
surface markers in BMCs 
  BMCs are one of the main immune cell reservoirs in 
hosts. To determine the recovery effects of fucoidan on the 
immune function of irradiated BMCs, we measured the 
expression levels of some important cell surface markers. 
By flow cytometric analyses (Fig. 4), we found that a 
phenotypic marker for granulocytes, Gr-1 expression, was 
significantly increased by fucoidan treatment. In contrast, 
the expression of immune-related markers, B7.2 (data not 
shown) and MHC II, were not significantly altered. Our 
results demonstrated that fucoidan significantly increases 
the expression of a granulocyte marker on BMCs, 
suggesting that this agent may facilitate proportional 
changes of cell types in BMCs and preferentially protect 
granulocytes in BMCs from growth factor-withdrawal or 
irradiation induced cell death.
Fucoidan treatment enhances BMC cytokine production 
  We investigated whether fucoidan-treated BMCs produce 
high levels of cytokines related to immune responses. IL-12 
and TNF-alpha were selected for this study as they are 
representative cytokines which are involved in cell- 
mediated and innate immunity, respectively. In ELISA (Fig. 
5), fucoidan significantly increased the production of IL-12 
in fucoidan-treated BMCs compared to control BMCs and 
increased the production of TNF-alpha in fucoidan-treated 
BMCs and fucoidan-treated irradiated BMCs compared to 
control BMCs and irraditated BMCs respectively. However, 
any significant increase of IL-12 was not detected in 
fucoidan-treated irradiated BMCs. These results suggest 
that fucoidan may alter cytokine production as well as cell 
viability.
Increased allogeneic splenocyte proliferation activated 
by fucoidan-treated BMCs
  The capacity of BMCs to activate the proliferation of 
allogeneic splenocytes was examined to determine whether 
fucoidan alters these immune responses. BMCs include 
various types of APCs as precursors or matured cells. Using 
MLR assays, BMCs of C57BL/6 mice were used as 
stimulators and splenocytes of Balb/c mice were used as 
allogeneic responder cells. To measure the proliferation of 
allogeneic splenocytes alone, all BMCs were irradiated 
immediately prior to co-culture. Fucoidan-treated BMCs 
and fucoidan-treated irradiated BMCs were found to have 
a significantly increased capability to enhance the proliferation 
of allogeneic responder cells compared to control BMCs and 
irradiated BMCs respectively (Fig. 6). These results suggest 
that fucoidan treatment significantly up-regulates APC 
functions of BMCs.Radioprotective effects of fucoidan    363
Fig. 4. Surface marker expression was up-regulated on bone 
marrow cells. (A) Numbers indicate the percentage of high 
expressed cells (M1) compared to that of fluorescence control. 
(B) Percentages of high expressed cells were analyzed 
statistically. An asterisk (*) indicate p ＜ 0.05 vs control. A sharp
(#) indicate p ＜ 0.05 vs IR control. 
Fig. 5. Fucoidan treatment enhances cytokine production of bone marrow cells (BMCs). The supernatants of BMCs were collected and
ELISA was performed to quantify cytokine concentrations. N/D: non-detectable level of cytokine. Asterisks (***) indicate p ＜ 0.001 
vs control. Sharps (###) indicate p ＜ 0.001 vs IR control.364    Yun-Young Byon et al.
Fig. 6. Fucoidan-treated bone marrow cells (BMCs) increases the
proliferation of allogeneic splenocytes. Allogeneic splenocytes 
(2 × 10
5 cells/well) were co-cultured with BMCs in 96-well culture
plates. Asterisks (**, ***) indicate p ＜ 0.01, 0.001 vs control, 
respectively. Sharps (###) indicate p ＜ 0.001 vs IR control.
Discussion
    Fucoidan is known to have a variety of biological 
functions, and the immunomodulatory activity of this 
agent has been studied extensively for many years. Recent 
studies demonstrated that fucoidan has significantly 
important biological effects on natural killer cells [13], 
hematopoietic stem cells [6], endothelial cells [11], and 
DCs [10]. Although the effects of fucoidan on the 
mobilization of HPCs in bone marrow have been studied 
well, there are few studies about the direct effects of 
fucoidan on BMCs. In this study, we investigated the 
radioprotective effects of fucoidan on BMCs by examining 
cell viability and immunostimulatory activity.
  Research on the development of radioprotective agents 
has focused on natural plant-derived compounds as 
potential candidates; medicinal herbs, including ginseng, 
are the main sources for the purification of effective 
candidates [7,18]. In a previous study, we demonstrated 
that ginsan, a polysaccharide from Panax ginseng, has 
radioprotective effects on BMCs [9]. Some biological 
response modifiers, including those consisting of 
polysaccharides, have been shown to have radioprotective 
and immunostimulatory effects. Immunostimulatory 
signaling is thought to transduce the survival signal in 
immune cells and is then manifested as radioprotective 
activity.
    On flow cytometric analysis, fucoidan-treated BMCs 
showed higher levels of surface Gr-1 expression than 
controls. As bone marrow is the main cellular source for 
the hematopoietic and immune systems, it contains large 
numbers of lymphocytes, granulocytes, and stromal cells 
as precursors and mature cells. Our results suggested that a 
specific population of BMCs, such as Gr-1
+ granulocytes, 
may selectively survive in response to fucoidan treatment 
following irradiation. Future research should focus on 
determining which cell types are selected by fucoidan and 
the mechanism of action of this agent.
  To investigate how fucoidan protects BMCs from cell 
death, the expression levels of apoptosis-related molecules 
were measured by Western blot analysis. Among the 
molecules belonging to the Bcl-2 family, Bcl-2, Bcl-xL, and 
Bax were selected due to their connection to apoptotic 
pathways involving mitochondria [4,14]. In addition, the 
levels of expression of cIAP-1 and cIAP-2, other anti- 
apoptotic molecules [12,16,20] were examined in the same 
experiments. We found that the levels of expression of Bcl-2, 
Bax, and cIAP-1 were higher in fucoidan-treated BMCs as 
compared with controls; there were no differences in cIAP-2 
expression between treated and control BMCs. Bcl-2 and 
Bax proteins show anti-apoptotic and pro-apoptotic effects, 
respectively. However, both were upregulated in the present 
study. It is possible that enhanced Bcl-2 expression may 
compensate for the activity of Bax and other anti-apoptotic 
molecules, such as cIAP-1 also may support the process. 
And also, there is another possibility that fucoidan may 
induce the cell death of some specific cell types whereas it 
enhances the survival of other cell types of BMCs. The 
effects of fucoidan on specific cell types of BMCs need to 
be investigated in future work.
  Our findings indicated that fucoidan-treated BMCs have 
an increased capability to stimulate allogeneic splenocytes 
as compared with controls. As fucoidan increased cytokine 
production, but not immune-related surface markers, it is 
postulated that the observed up-regulation of immune 
responses may be due primarily to increased cytokine 
production and a higher percentage of Gr-1
+ cells, including 
APCs within stimulator cells.
  Taken together, our results demonstrate that the sulfated 
polysaccharide fucoidan has radioprotective effects on 
BMCs. These effects include aspects of cell viability and 
immunomodulatory activity. In conclusion, the results of 
this study may facilitate the development of new 
radioprotective agents with reduced toxicity. 
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